Company profile: Sigrid THx
1.1 - Company Overview
Company description
- Provider of ingested medical devices and platform technologies to lower blood sugar in prediabetics and newly diagnosed type 2 diabetics. Offerings include SiPore21 and the SiPore platform using engineered silica particles acting in the gut without absorption. Conducts clinical trials, including SiPore15 and SiPore21, with potential future indications in obesity, NASH, and infantile colic.
Products and services
- SiPore®: Architects a platform-scale technology to develop metabolic disease treatments using engineered silica particles that work in the gut without being absorbed, supporting non-systemic therapeutic products
- SiPore21®: Engineers an ingestible medical device that lowers blood sugar levels in prediabetics and newly diagnosed type 2 diabetics, purpose-built for glycemic control
- Clinical Trials: Delivers clinical-stage studies to evaluate safety and efficacy of Sigrid Therapeutics’ products, including SiPore15® and SiPore21®
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sigrid THx
Ypsomed
HQ: Switzerland
Website
- Description: Provider of injection and infusion systems for self-medication, partnering with pharmaceutical and biotechnology companies for injection pens and autoinjectors. Delivers mylife Diabetescare solutions including infusion systems, blood glucose monitoring and therapy management, the mylife YpsoPump insulin pump, YpsoMate autoinjector, and mylife Loop automated insulin dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ypsomed company profile →
Satiogen
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies targeting type 2 diabetes, offering metabolic mechanism therapy designed to regulate nutrient intake and postprandial glucose. Products include a substitute for metformin in gliptin formulations and an OTC nutraceutical.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satiogen company profile →
Reapplix
HQ: Denmark
Website
- Description: Provider of biological wound therapies that identify, isolate, and reapply blood-derived proteins to improve healing in chronic wounds, including the 3C Patch System made entirely from the patient’s own blood to accelerate healing of diabetic foot ulcers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reapplix company profile →
Orpyx
HQ: Canada
Website
- Description: Provider of sensor-based technologies and self-monitoring devices for medical and athletic applications, including the Orpyx SI Sensory Insole System to monitor plantar pressure, adherence, step count, and temperature for peripheral neuropathy patients to reduce diabetic foot ulcer risk. Offers remote patient monitoring with data science-based triage by credentialed providers and nurses and a Diabetes Healthspan Extension for personalized remote care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orpyx company profile →
Rubin Medical
HQ: Sweden
Website
- Description: Provider of diabetes aids for the public and healthcare sectors as a pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubin Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sigrid THx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sigrid THx
2.2 - Growth funds investing in similar companies to Sigrid THx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sigrid THx
4.2 - Public trading comparable groups for Sigrid THx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →